Brainstorm Cell Therapeutics (BCLI) Tops Q3 EPS by 5c; Reports Cash and Cash Equivalents of $28M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/28/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts BCLI Hot Sheet
Join SI Premium – FREE
Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q3 EPS of ($0.15), $0.05 better than the analyst estimate of ($0.20).
For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- OneSpaWorld Holdings Ltd. (OSW) Tops Q3 EPS by 3c ; Offers Guidance
- Smurfit Westrock Plc (SW) Misses Q3 EPS by 15c, Misses on Revenue
- HF Sinclair Corporation (DINO) Tops Q3 EPS by 408c
Create E-mail Alert Related Categories
Corporate News, EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
